Herceptin Metastatic Breast Cancer Effect Rivals Taxol - ASCO Discussant
Executive Summary
The efficacy of Genentech's Herceptin rivals Bristol's Taxol and other preferred agents for refractory metastatic breast cancer, discussant Edison Liu, MD, National Cancer Institute, told the American Society of Clinical Oncology May 17 in Los Angeles.